Zobrazeno 1 - 10
of 1 382
pro vyhledávání: '"Stefano, Cascinu"'
Autor:
Margherita Rimini, Margarida Montes, Elisabeth Amadeo, Francesco Vitiello, Masatoshi Kudo, Toshifumi Tada, Goki Suda, Shigeo Shimose, Sara Lonardi, Fabian Finkelmeier, Francesca Salani, Lorenzo Antonuzzo, Fabio Marra, Massimo Iavarone, Giuseppe Cabibbo, Francesco Giuseppe Foschi, Marianna Silletta, Rodolfo Sacco, Ilario Giovanni Rapposelli, Mario Scartozzi, Pella Nicoletta, Luca Aldrighetti, Mara Persano, Silvia Camera, Federico Rossari, Silvia Foti, Takashi Kumada, Atsushi Hiraoka, Hideki Iwamoto, Mario Domenico Rizzato, Vera Himmelsbach, Gianluca Masi, Mattia Corradi, Ciro Celsa, Conti Fabio, Giovanni Luca Frassineti, Stefano Cascinu, Andrea Casadei-Gardini, Jose Presa
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-14 (2024)
Abstract Recently, in Hepatocellular carcinoma (HCC) setting, the use of metformin has been associated to a trend toward worse response rate, overall survival and progression free survival in patients who received immunotherapy. The study population
Externí odkaz:
https://doaj.org/article/41799d524b5a43689733a5a5474189a2
Autor:
Paolo Passoni, Michele Reni, Sara Broggi, Najla Slim, Andrei Fodor, Marina Macchini, Giulia Orsi, Umberto Peretti, Gianpaolo Balzano, Domenico Tamburrino, Giulio Belfiori, Stefano Cascinu, Massimo Falconi, Claudio Fiorino, Nadia Di Muzio
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 47, Iss , Pp 100778- (2024)
Background and purpose: To assess feasibility, toxicity and outcome of moderately hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic cancer. Materials and methods: Patients with advanced pan
Externí odkaz:
https://doaj.org/article/df121c718d9043a5abc16039b5a3a16a
Autor:
Francesco Vitiello, Stefano Cereda, Silvia Foti, Nicole Liscia, Elena Mazza, Monica Ronzoni, Stefano Cascinu
Publikováno v:
Immunological Medicine, Vol 47, Iss 1, Pp 1-5 (2024)
AbstractSmall bowel adenocarcinoma (SBA) is a rare tumor with an unfavorable prognosis, and due to its rarity, few studies on its treatment are available. Chemotherapy remains the standard of treatment in advanced disease. Recently immunotherapy has
Externí odkaz:
https://doaj.org/article/6b99de4964474cd4b9d0055f294478ae
Autor:
Federico Rossari, Toshifumi Tada, Goki Suda, Shigeo Shimose, Masatoshi Kudo, Changhoon Yoo, Jaekyung Cheon, Fabian Finkelmeier, Ho Yeong Lim, José Presa, Gianluca Masi, Francesca Bergamo, Elisabeth Amadeo, Francesco Vitiello, Takashi Kumada, Naoya Sakamoto, Hideki Iwamoto, Tomoko Aoki, Hong Jae Chon, Vera Himmelsbach, Massimo Iavarone, Giuseppe Cabibbo, Margarida Montes, Francesco Giuseppe Foschi, Caterina Vivaldi, Caterina Soldà, Takuya Sho, Takashi Niizeki, Naoshi Nishida, Christoph Steup, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Ochi, Satoshi Yasuda, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Noritomo Shimada, Kazuhito Kawata, Atsushi Hiraoka, Fujimasa Tada, Hideko Ohama, Kazuhiro Nouso, Asahiro Morishita, Akemi Tsutsui, Takuya Nagano, Norio Itokawa, Tomomi Okubo, Michitaka Imai, Hisashi Kosaka, Atsushi Naganuma, Yohei Koizumi, Shinichiro Nakamura, Masaaki Kaibori, Hiroko Iijima, Yoichi Hiasa, Mara Persano, Silvia Foti, Silvia Camera, Bernardo Stefanini, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini, Margherita Rimini
Publikováno v:
Liver Cancer (2024)
Introduction The impact of etiology on response to immunotherapy in advanced hepatocellular carcinoma (HCC) is being debated, with contrasting findings between early and recent post-hoc analyses of IMbrave-150 and metanalyses of clinical trials of PD
Externí odkaz:
https://doaj.org/article/3da67a4e9b81471598019e46c12fc527
Autor:
Luca Licata, Giulia Viale, Mario Giuliano, Giuseppe Curigliano, Mariana Chavez-MacGregor, Julia Foldi, Oluchi Oke, Joseph Collins, Lucia Del Mastro, Fabio Puglisi, Filippo Montemurro, Claudio Vernieri, Lorenzo Gerratana, Sara Giordano, Alessia Rognone, Lorenzo Sica, Oreste Davide Gentilini, Stefano Cascinu, Lajos Pusztai, Antonio Giordano, Carmen Criscitiello, Giampaolo Bianchini
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-7 (2023)
Abstract Adjuvant chemotherapy recommendations for ER+/HER2− early-stage breast cancers (eBC) involve integrating prognostic and predictive information which rely on physician judgment; this can lead to discordant recommendations. In this study we
Externí odkaz:
https://doaj.org/article/71af898d79424e0aa99424fea6092b45
Autor:
Margherita Rimini, Carles Fabregat-Franco, Valentina Burgio, Sara Lonardi, Monica Niger, Mario Scartozzi, Ilario Giovanni Rapposelli, Giuseppe Aprile, Francesca Ratti, Federica Pedica, Helena Verdaguer, Mario Rizzato, Federico Nichetti, Eleonora Lai, Alessandro Cappetta, Teresa Macarulla, Matteo Fassan, Filippo De Braud, Andrea Pretta, Francesca Simionato, Francesco De Cobelli, Luca Aldrighetti, Lorenzo Fornaro, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-12 (2022)
Abstract IDH1-mutated cholangiocarcinomas (CCAs) are an interesting group of neoplasia with particular behavior and therapeutic implications. The aim of the present work is to highlight the differences characterizing IDH1m and IDH1wt CCAs in terms of
Externí odkaz:
https://doaj.org/article/49008ad5b7a4484585f1c9926745098f
Autor:
Margherita Rimini, Valentina Burgio, Lorenzo Antonuzzo, Lorenza Rimassa, Ester Oneda, Caterina Soldà, Pasqua Cito, Guglielmo Nasti, Daniele Lavacchi, Valentina Zanuso, Mario Domenico Rizzato, Alberto Zaniboni, Alessandro Ottaiano, Mara Persano, Noemi Cornara, Mario Scartozzi, Stefano Cascinu, Andrea Casadei-Gardini
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: The results of the phase III ClarIDHy trial led to the FDA approval of ivosidenib as a therapeutic option for patients with locally advanced or metastatic cholangiocarcinoma (CCA) harboring isocitrate dehydrogenase 1 (IDH1) mutations. We
Externí odkaz:
https://doaj.org/article/69f677a554184995a75623a191483dc2
Autor:
Stefano Cascinu, Maria Di Bartolomeo, Sara Lonardi, Giordano Beretta, Lorenzo Fornaro, Ferdinando De Vita
Publikováno v:
Frontiers in Medicine, Vol 9 (2022)
Gastric cancer (GC) is recognized as one of the most common deadly malignancies worldwide and about 40–50% of patients present at diagnosis with an unresectable disease due to a locally advanced or already metastatic condition. Recently, therapeuti
Externí odkaz:
https://doaj.org/article/631a15ab8ef749eb86d8e9524296b32f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Andrea Casadei-Gardini, Margherita Rimini, Masatoshi Kudo, Shigeo Shimose, Toshifumi Tada, Goki Suda, Myung Ji Goh, Andre Jefremow, Mario Scartozzi, Giuseppe Cabibbo, Claudia Campani, Emiliano Tamburini, Francesco Tovoli, Kazuomi Ueshima, Tomoko Aoki, Hideki Iwamoto, Takuji Torimura, Takashi Kumada, Atsushi Hiraoka, Masanori Atsukawa, Ei Itobayashi, Hidenori Toyoda, Naoya Sakamoto, Takuya Sho, Wonseok Kang, Jürgen Siebler, Markus Friedrich Neurath, Valentina Burgio, Stefano Cascinu
Publikováno v:
Liver Cancer (2022)
Introduction: In the REFLECT trial, lenvatinib was found to be non-inferior compared to sorafenib in terms of Overall Survival. Here, we analyze the effects of lenvatinib in the real-life experience of several centers across the world, and to identif
Externí odkaz:
https://doaj.org/article/08c68969bf5f4251a200dc0cdcbbbea5